Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netakimab - Biocad

Next Previous
Drug Profile

Netakimab - Biocad

Alternative Names: Anti-IL-17-monoclonal-antibody-Biocad; Anti-interleukin-17-monoclonal-antibody-Biocad; BCD 085; Efleira

Latest Information Update: 16 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; SPH-BIOCAD
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Hepatoprotectants; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 16 May 2025 SPH-BIOCAD completes a phase-III clinical trials in Ankylosing spondylitis in China (SC) (NCT07277179)
  • 24 Aug 2023 Phase-III clinical trials in Ankylosing spondylitis in China (SC), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)
  • 24 Aug 2023 Phase-III clinical trials in Plaque psoriasis in China (SC), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top